Crescent pitches CLO equity to insurers as a distribution play

Insurers rarely raise their hand for CLO equity, the first-loss slice of a securitization whose return depends on loan defaults and recoveries rather than a promised coupon. Yet Creditflux reports that Crescent's CLO equity fund has pulled in capital-charge-sensitive insurers, and the pitch from the firm's head of tradeable credit is built on cash-on-cash distributions.

John Fekete, Crescent's head of tradeable credit, told Creditflux that cash-on-cash distributions look particularly attractive as private equity struggles with returning distributions to investors, a pitch aimed directly at allocators who have watched PE distribution schedules slip year after year. When the underlying loans behave, CLO equity sends cash out the door, and a quarterly check is an easier conversation with an insurance investment committee than a mark-to-model on a portfolio company.

The vehicle is Crescent's sophomore CLO equity fund, which closed at $232m in late August, more than double its 2018 debut. That close signaled allocators still want the first-loss slice even as debt resets compress spreads. Creditflux's report does not say whether the insurer commitments are inside that $232m close or came after, but the timing suggests the capital-charge conversation is happening right on top of the fund's final close.

Capital-charge-sensitive insurers are weighing the cost of holding the first-loss exposure against the cost of holding other private credit instruments, and the cash-on-cash yield is what tips the scale. The report does not detail the regulatory arithmetic that makes the trade work for this group.

The backdrop is the reset wave that ran through the summer, including a week in which four managers priced nearly $2bn of US CLO resets. Those reset trades lowered liability costs and made the equity tranche's cash flows look better relative to the rest of the stack. The reset cycle is not a one-quarter trade; it is the permanent funding mechanism for private credit books—Crescent's insurer marketing is the first-loss product being built to arbitrage that cycle, and the $232m close is the proof of demand.

The twist is that Crescent is selling CLO equity specifically as a distribution product, and Fekete's emphasis on cash-on-cash rather than total return or spread is the tell. When a manager selling a structured credit product leads with the cash distribution, the message is that the asset has been redesigned for the income column—a different sell than the historical pitch about the arbitrage between the equity's excess spread and the debt's funding cost.

The strategy is understandable and probably right for this moment, but the income pitch obscures the residual nature of the claim: a CLO equity fund that attracts insurers on a cash-on-cash number is taking on a liability that has to survive a downturn in the loan market to keep paying. The managers that win will be those who have structured the underlying portfolios to keep distributions flowing through stress—static deals of seasoned loans, not freshly issued credits written at the top of the cycle.

The structure is broadening in other directions too: Sona priced Europe's first hybrid BSL-private credit CLO in August, and Eagle Point is readying an infrastructure CLO. Those moves stretch the collateral, but the insurer bid for Crescent's fund stretches the investor base, which is arguably the more important extension. If insurers become a regular presence at the bottom of CLO liabilities, the equity tranche will start to be priced for them, with all the emphasis on cash yields and capital charges that implies.

Crescent has a $232m CLO equity fund that has drawn a new class of buyer, and the selling point is a cash yield that private equity cannot currently match. The distribution drought in private markets is making every instrument that pays out look more appealing. Given the way the pitch is phrased, the insurers are in for the yield; the first downturn that interrupts a distribution will show whether they understood the residual risk.